Advances of Cancer Therapy by Nanotechnology

키워드

참고문헌 (146)

1. Qiu LY, "Polymer architecture and drug delivery", Pharm Res, 23, pp.1~30 (2006)
2. Tong R, "Anticancer polymeric nanomedicines", Polym Rev, 47, pp.345~381 (2007)
3. Cho K, "Therapeutic nanoparticles for drug delivery in cancer", Clin Cancer Res, 14, pp.1310~1316 (2008)
4. Zhang GZ, "Formation of novel polymeric nanoparticles", Acconuts Chem Res, 34, pp.249~256 (2001)
5. Park K, "Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates", Langmuir, 20, pp.11726~11731 (2004)
6. Park K, "Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity", J Control Release, 114, pp.300~306 (2006)
7. Kratz F, "Drug-polymer conjugates containing acid-cleavable bonds", Crit Rev Ther Drug, 16, pp.245~288 (1999)
8. Ulbrich K, "Polymeric anticancer drugs with pH-controlled activation", Adv Drug Deliver Rev, 56, pp.561023~561050 (2004)
9. Jones DP, "Glutathione measurement in human plasma Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC", Clin Chim Acta, 275, pp.175~184 (1998)
10. Koo AN, "Disulfide-cross-linked PEGpoly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery", Chem Comm, pp.6570~6572 (2008)
11. Bosman AW, "About dendrimers: Structure, physical properties, and applications", Chem Rev, 99, pp.1665~1688 (1999)
12. Fischer M, "Dendrimers: From design to application - A progress report", Angew Chem Int Edit, 38, pp.885~905 (1999)
13. Klajnert B, "Dendrimers: properties and applications", Acta Biochimica Polonica, 48, pp.199~208 (2001)
14. Dykes GM, "Dendrimers: a review of their appeal and applications", J Chem Tech Biot, 76, pp.903~918 (2001)
15. Esfand R, "Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications", Drug Discov Today, 6, pp.427~436 (2001)
16. Balogh L, "Poly(amidoamine) dendrimer-templated nanocomposites. 1. Synthesis of zerovalent copper nanoclusters", J Am Chem Soc, 120, pp.7355~7356 (1998)
17. Crooks RM, "Dendrimer-encapsulated metal nanoparticles: Synthesis, characterization, and applications to catalysis", Acconuts Chem Res, 34, pp.181~190 (2001)
18. Balogh L, "Dendrimer nanocomposites in medicine", Chim Oggi, 20, pp.35~40 (2002)
19. Zheng J, "Individual water-soluble dendrimer-encapsulated silver nanodot fluorescence", J Am Chem Soc, 124, pp.13982~13983 (2002)
20. Bangham AD, "Negative Staining of Phospholipids + Their Structural Modification by-Surface Active Agents as Observed in Electron Microscope", J Mol Biol, 8, pp.660~668 (1964)
21. Watwe RM, "Manufacture of Liposomes - a Review", Curr Sci, 68, pp.715~724 (1995)
22. Gabizon AA, "Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet", Clin Cancer Res, 7, pp.223~225 (2001)
23. Cheng Y, "Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer", J Am Chem Soc, 130, pp.10643~10647 (2008)
24. Qian X, "In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags", Nat Biotechnol, 26, pp.83~90 (2008)
25. Dewey WC, "Arrhenius Relationships from the Molecule and Cell to the Clinic", Int J Hyperther, 10, pp.457~483 (1994)
26. Sun C, "Magnetic nanoparticles in MR imaging and drug delivery", Adv Drug Deliver Rev, 60, pp.1252~1265 (2008)
27. Jun YW, "Chemical design of nanoparticle probes for highperformance magnetic resonance imaging", Angew Chem Int Edit, 47, pp.5122~5135 (2008)
28. Xu CJ, "Monodisperse magnetic nanoparticles for biomedical applications", Polym Int, 56, pp.821~826 (2007)
29. Davis ME, "Nanoparticle therapeutics: an emerging treatment modality for cancer", Nat Rev Drug Discov, 7, pp.771~782 (2008)
30. Gao X, "In vivo cancer targeting and imaging with semiconductor quantum dots", Nat Biotechnol, 22, pp.969~976 (2004)
31. Jain TK, "Iron oxide nanoparticles for sustained delivery of anticancer agents", Mol Pharm, 2, pp.194~205 (2005)
32. Pelicano H, "Glycolysis inhibition for anticancer treatment", Oncogene, 25, pp.4633~4646 (2006)
33. Deryugina EI, "Matrix metalloproteinases and tumor metastasis", Cancer Metastasis Rev, 25, pp.9~34 (2006)
34. Edens HA, "Neutrophil transepithelial migration: evidence for sequential, contact-dependent signaling events and enhanced paracellular permeability independent of transjunctional migration", J Immunol, 169, pp.476~486 (2002)
35. Wang X, "Application of nanotechnology in cancer therapy and imaging", CA Cancer J Clin, 58, pp.97~110 (2008)
36. Jain RK, "Transport of molecules across tumor vasculature", Cancer Metastasis Rev, 6, pp.559~593 (1987)
37. Brannon-Peppas L, "Nanoparticle and targeted systems for cancer therapy", Adv Drug Deliv Rev, 56, pp.1649~1659 (2004)
38. Cuenca AG, "Emerging implications of nanotechnology on cancer diagnostics and therapeutics", Cancer, 107, pp.459~466 (2006)
39. Allen TM, "Drug delivery systems: entering the mainstream", Science, 303, pp.1818~1822 (2004)
40. Sutton D, "Functionalized micellar systems for cancer targeted drug delivery", Pharm Res, pp.1029~1046 (2007)
41. Weissig V, "Accumulation of protein-loaded longcirculating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice", Pharm Res, 15, pp.1552~1556 (1998)
42. Papahadjopoulos D, "Liposomes designed to avoid the reticuloendothelial system", Prog Clin Biol Res, 343, pp.85~93 (1990)
43. Wagner V, "The emerging nanomedicine landscape", Nat Biotechnol, 24, pp.1211~1217 (2006)
44. Sparreboom A, "Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albuminbound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)", Clin Cancer Res, 11, pp.4136~4143 (2005)
45. Boddy AV, "A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules", Clin Cancer Res, 11, pp.7834~7840 (2005)
46. Schluep T, "Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice", Cancer Chemother Pharmacol, 57, pp.654~662 (2006)
47. Gradishar WJ, "Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oilbased paclitaxel in women with breast cancer", J Clin Oncol, 23, pp.7794~7803 (2005)
48. Hamaguchi T, "NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel", Br J Cancer, 92, pp.1240~1246 (2005)
49. Kato K, "Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle in patients with advanced cancer", Proc Am Soc Clin Oncol, 24, pp.83S~ (2006)
50. Hamaguchi T, "A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation", Br J Cancer, 97, pp.170~176 (2007)
51. Charrois GJ, "Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer", Biochim Biophys Acta, 1663, pp.167~177 (2004)
52. Matsumura Y, "Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin", Br J Cancer, 91, pp.1775~1781 (2004)
53. Stohrer M, "Oncotic pressure in solid tumors is elevated", Cancer Res, 60, pp.4251~4255 (2000)
54. Kirpotin DB, "Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models", Cancer Res, 66, pp.6732~6740 (2006)
55. Bartlett DW, "Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging", Proc Natl Acad Sci U S A, 104, pp.15549~15554 (2007)
56. Farokhzad OC, "Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo", Proc Natl Acad Sci U S A, 103, pp.6315~6320 (2006)
57. Gu F, "Radovic-Moreno AF, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers", Proc Natl Acad Sci U S A, 105, pp.2586~2591 (2008)
58. Matsumura Y, "Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer", Ann Oncol, 15, pp.517~525 (2004)
59. [URL]
60. [URL]
61. Heidel JD, "Administration in nonhuman primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA", Proc Natl Acad Sci U S A, 104, pp.5715~5721 (2007)
62. [URL]
63. Gatter KC, "Transferrin receptors in human tissues: their distribution and possible clinical relevance", J Clin Pathol, 36, pp.539~545 (1983)
64. Dhar S, "Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles", Proc Natl Acad Sci U S A, 105, pp.17356~17361 (2008)
65. Mansour AM, "malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2", Cancer Res, 63, pp.4062~4066 (2003)
66. Kong G, "Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release", Cancer Res, 60, pp.6950~6957 (2000)
67. Guillemard V, "Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity", Oncogene, 23, pp.3613~3621 (2004)
68. Guillemard V, "Novel approaches for targeted cancer therapy", Curr Cancer Drug Targets, 4, pp.313~326 (2004)
69. Pechar M, "Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin", Bioconjug Chem, 11, pp.131~139 (2000)
70. Lu ZR, "Modification of cyclosporin A and conjugation of its derivative to HPMA copolymers", Bioconjug Chem, 12, pp.129~133 (2001)
71. Li C, "Poly(L-glutamic acid)--anticancer drug conjugates", Adv Drug Deliv Rev, 54, pp.695~713 (2002)
72. Sudimack J, "Targeted drug delivery via the folate receptor", Adv Drug Deliv Rev, 41, pp.147~162 (2000)
73. Ni S, "Folate receptor targeted delivery of liposomal daunorubicin into tumor cells", Anticancer Res, 22, pp.2131~2135 (2002)
74. Backer MV, "Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery", Protein Expr Purif, 26, pp.455~461 (2002)
75. Backer MV, "Molecular vehicles for targeted drug delivery", Bioconjug Chem, 13, pp.462~467 (2002)
76. Saba NF, "Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug" (2008), Head and Neck
77. Ferry DR, "Clinical trials of P-glycoprotein reversal in solid tumours", Eur J Cancer, 32A, pp.1070~1081 (1996)
78. McDevitt CA, "How can we best use structural information on Pglycoprotein to design inhibitors?", Pharmacol Ther, 113, pp.429~441 (2007)
79. Pepin X, "On the use of ionpair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level", J Chromatogr B Biomed Sci Appl, 702, pp.181~191 (1997)
80. Vauthier C, "Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles", J Control Release., 93, pp.151~160 (2003)
81. Peracchia MT, "Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting", J Control Release, 60, pp.121~128 (1999)
82. Schluep T, "Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models", Clin Cancer Res, 12, pp.1606~1614 (2006)
83. Northfelt DW, "Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy", J Clin Oncol, 15, pp.653~659 (1997)
84. Mamot C, "Liposome-based approaches to overcome anticancer drug resistance", Drug Resist Updat, 6, pp.271~279 (2003)
85. Lee KS, "Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer", Breast Cancer Res Treat, 108, pp.241~250 (2008)
86. Nemunaitis J, "Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors", Cancer Invest, 23, pp.671~676 (2005)
87. Lee ES, "Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor", J Control Release, 103, pp.405~418 (2005)
88. Sahoo SK, "Enhanced antiproliferative activity of transferrinconjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention", Mol Pharm, 2, pp.373~383 (2005)
89. Rihova B, "Immunological problems of polymer-bound drugs", Crit Rev Ther Drug Carrier Syst, 1, pp.311~374 (1985)
90. Duncan R, "The dawning era of polymer therapeutics", Nat Rev Drug Discov, 2, pp.347~360 (2003)
91. Cagle DW, "In vivo studies of fullerenebase d materials using endohedral metallofullerene radiotracers", Proc Natl Acad Sci U S A, 96, pp.5182~5187 (1999)
92. Ogawara K, "Surface hydrophobicity of particles is not necessarily the most important determinant in their in vivo disposition after intravenous administration in rats", J Control Release, 77, pp.191~198 (2001)
93. Fernandez-Urrusuno R, "Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles", Toxicol Appl Pharmacol, 130, pp.272~279 (1995)
94. Roberts JC, "Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers", J Biomed Mater Res, 30, pp.53~65 (1996)
95. Neerman MF, "In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery", Int J Pharm, 281, pp.29~32 (2004)
96. Wang B, "Acute toxicity of nanoand micro-scale zinc powder in healthy adult mice", Toxicol Lett, 161, pp.115~123 (2006)
97. Meerum Terwogt JM, "Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel", Anticancer Drugs, 12, pp.315~323 (2001)
98. Wachters FM, "A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours", Br J Cancer, 90, pp.2261~2267 (2004)
99. Clift MJ, "The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line", Toxicol Appl Pharmacol, 232, pp.418~427 (2008)
100. Kukowska-Latallo JF, "Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer", Cancer Res, 65, pp.5317~5324 (2005)
101. Benny O, "An orally delivered small-molecule formulation with antiangiogenic and anticancer activity", Nat Biotechnol, 26, pp.799~807 (2008)
102. Langer CJ, "CT-2103: emerging utility and therapy for solid tumours", Expert Opin Investig Drugs, 13, pp.1501~1508 (2004)
103. Rahman AM, "Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation", Int J Nanomedicine, 2, pp.567~583 (2007)
104. Batist G, "Cardiac safety of liposomal anthracyclines", Cardiovasc Toxicol, 7, pp.72~74 (2007)
105. Fassas A, "The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia", Leuk Lymphoma, 46, pp.795~802 (2005)
106. Allison SD, "Liposomal drug delivery", J Infus Nurs, 30, pp.89~95 (2007)
107. Sapra P, "Ligand-targeted liposomes for cancer treatment", Curr Drug Deliv, 2, pp.369~81 (2005)
108. White SC, "Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer", Br J Cancer, 95, pp.822~828 (2006)
109. Rosenthal DI, "A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer", Invest New Drugs, 20, pp.343~349 (2002)
110. Harrington KJ, "Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer", Ann Oncol, 12, pp.493~496 (2001)
111. Neville ME, "Biopharmaceutics of liposomal interleukin 2, oncolipin", Cytokine, 12, pp.1691~1701 (2000)
112. Ciuleanu T, "A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)", leucovorin (LV) as first-line treatment in patients with advanced biliary cancers, 2007, pp.25, 385~390
113. Clamp AR, "A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer", Cancer Chemother Pharmacol, 61, pp.579~585 (2008)
114. Guo W, "Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study", Anal Biochem, 336, pp.213~220 (2005)
115. Seiden MV, "A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer", Gynecol Oncol, 93, pp.229~232 (2004)
116. Dragovich T, "A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer", Cancer Chemother Pharmacol, 58, pp.759~764 (2006)
117. Kim DW, "Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer", Ann Oncol, 18, pp.2009~2014 (2007)
118. Kim SI, "Systemic and Specific Delivery of Small Interfering RNAs to the Liver Mediated by Apolipoprotein A-I", Mol Ther, pp.1145~1152 (2007)
119. Kim TY, "Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelleformulated paclitaxel, in patients with advanced malignancies", Clin Cancer Res, 10, pp.3708~3716 (2004)
120. Matsumura Y, "Micelle carrier system in clinical trial", Nippon Rinsho, 64, pp.316~321 (2006)
121. Danson S, "Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer", Br J Cancer, 90, pp.2085~2091 (2004)
122. Uchino H, "Cisplatinincorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats", Br J Cancer, 93, pp.678~687 (2005)
123. Koizumi F, "Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors", Cancer Res, 66, pp.10048~10056 (2006)
124. Negishi T, "NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel", Br J Cancer, 95, pp.601~606 (2006)
125. Albain KS, "PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapynaive women with advanced-stage non-small-cell lung cancer and performance status of 2", Clin Lung Cancer, 7, pp.417~419 (2006)
126. Bilim V, "Technology evaluation: PK1, Pfizer", Cancer Research UK, 2003, pp.5, 326~330
127. Thomson AH, "Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours", Br J Cancer, 81, pp.99~107 (1999)
128. Seymour LW, "Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin", J Clin Oncol, 20, pp.1668~1676 (2002)
129. Bissett D, "Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)", Br J Cancer, 91, pp.50~55 (2004)
130. Sarapa N, "Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma", Cancer Chemother Pharmacol, 52, pp.424~430 (2003)
131. Rademaker-Lakhai JM, "A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors", Clin Cancer Res, 10, pp.3386~3395 (2004)
132. Campone M, "Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer onjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients", Cancer Chemother Pharmacol, 60, pp.523~533 (2007)
133. Danhauser-Riedl S, "Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD)", Invest New Drugs, 11, pp.187~195 (1993)
134. Shiose Y, "Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f", J Pharm Biomed Anal, 43, pp.1290~1296 (2007)
135. Soepenberg O, "Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors", Clin Cancer Res, 11, pp.703~711 (2005)
136. Ochi Y, "A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951", Cancer Chemother Pharmacol, 55, pp.323~332 (2005)
137. Greenwald RB, "Effective drug delivery by PEGylated drug conjugates", Adv Drug Deliv Rev, 55, pp.217~250 (2003)
138. Rowinsky EK, "A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies", J Clin Oncol, 21, pp.148~157 (2003)
139. Sapra P, "Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11- refractory model", Clin Cancer Res, 14, pp.1888~1896 (2008)
140. "NektarTherapeutics. Study to Evaluate the Safety and Efficacy of NKTR-102 (PEGIrinotecan) in Patients With Metastatic or Locally Advanced Breast Cancer. Clinical Trials.gov web site 2008"[URL]
141. Gradishar WJ, "Albumin-bound nanoparticle paclitaxel", Clin Adv Hematol Oncol, 3, pp.348~349 (2005)
142. Gradishar WJ, "Albumin-bound paclitaxel: a next-generation taxane", Expert Opin Pharmacother, 7, pp.1041~1053 (2006)
143. Yoo HS, "Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate", J Control Release, 100, pp.247~256 (2004)
144. Nasongkla N, "cRGDfunctionalized polymer micelles for targeted doxorubicin delivery", Angew Chem Int Ed Engl, 43, pp.6323~6327 (2004)
145. Torchilin VP, "Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs", Proc Natl Acad Sci U S A, 100, pp.6039~6044 (2003)
146. Jeong YI, "Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl Lglutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety", Int J Pharm, 296, pp.151~161 (2005)

관련 논문AI추천